PS 341 is a potent and selective inhibitor of the proteasome.

PS 341是蛋白酶体有效的选择性抑制药。

EIN3 is regulated by a proteasome-mediated protein degradation pathway.

EIN3受到蛋白酶体介导的蛋白降解途径的调节。

Bortezonib (velcade) is the first proteasome inhibitor that has entered clinical trial.

波替单抗(万珂)是第一个进入临床试验的蛋白酶体抑制剂。

Proteasome inhibitors can selectively promote the apoptosis of tumor cells and overcome MDR.

蛋白酶体抑制剂可选择性地促进肿瘤细胞凋亡，逆转多药耐药。

Pharmacodynamic assay has shown that inhibition of proteasome is dose dependent and reversible.

药效学分析表明蛋白酶体抑制药的抑制作用有剂量依赖性和可逆性。